Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT02642068 |
Other study ID # |
201401024RINC |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
August 1, 2014 |
Est. completion date |
July 31, 2019 |
Study information
Verified date |
September 2021 |
Source |
National Taiwan University Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
We anticipate that drug-naïve ADHD probands, particularly those with DAT1 or SLC6A2 gene
variants may have higher level of altered microstructural integrity of frontostriatal (FS),
frontoparietal (FP), other hypothesized fiber tracts and decreased brain activity of FS, FP,
and other circuits, deficits in ERP, and impaired EF, SA, IIA and VM than probands without
DAT1 or SLC6A2 gene variants or adult neurotypical. The alterations in the structural and
functional connectivity, neurophysiological and neuropsychological functioning would be
observed in the unaffected siblings as compared to neurotypical. The unaffected siblings will
be in the intermediate position between drug-naïve adult ADHD probands and neurotypical. The
genetic dosage is anticipated to pose the strongest effects on the cortical thickness, brain
volume, gyrification and microstructural property of white matter, followed by
neurophysiology, functional connectivity, and neuropsychological function with the least
effect.
In terms of longitudinal follow-up part, we also anticipated despite increasing thinning of
cortical thickness, microstructural integrity of several targets fiber tracts, and brain
activity of target brain regions and improving performance in EF, SA, IIV, VM from childhood
to late adolescence and young adulthood in the neurotypical group, the slopes of
developmental trajectories of these neuroimaging and neuropsychological function are lower in
the ADHD group.
Description:
Attention deficit/hyperactivity disorder (ADHD) is a common (3-10%), early-onset, clinically
and genetically heterogeneous neuropsychiatric disorder with lifelong neuropsychological
deficits. Despite extensive research in adult ADHD in western countries, there has been no
published data about adult ADHD in Taiwan except the PI's and colleagues' previous works on
pharmacotherapy in adults with ADHD and only few endophenotype studies based on adults with
ADHD in the world. The ultimate goals of this 5-year project are to identify which
neuropsychological, functional and structural connectivity, and neurophysiological variables
can be effective endophenotypes (biomarkers) for ADHD based on unaffected sibling (1st-3rd
years) and follow-up (4th-5th years) designs. With the accomplishment of the following study
goals, this study will be the first study on the topics of neuroimaging and
neurophysiological endophenotypes on adult ADHD using advanced imaging techniques (i.e.,
Tract-based autonomic analysis, TBAA) and comprehensive clinical and neurocognitive data.
This proposal has one primary aim and four secondary aims:
Primary Aim:
1. To validate structural (assessed by TBAA using diffusing spectrum imaging, DSI) and
functional connectivity (assessed by resting-state fMRI) in frontostriatal,
frontoparietal and other circuitries, and neurophysiological functions (assessed by
stop-signal event-related potential [ERP]: N2, P3, ERN, Pe) as effective imaging
endophenotypes by demonstrating the intermediate position of unaffected siblings between
ADHD probands, and age-, sex-, handedness-, and IQ-matched adult neurotypical and
association with DAT1 and NET (SLC6A2) variants;
Secondary Aims:
2. To validate the executive functions (EF), sustained attention (SA), intraindividual
variability (IIV), visual-spatial memory (VM) as effective neurocognitive endophenotypes
by demonstrating the intermediate position of unaffected siblings between ADHD probands,
and adult neurotypical;
3. To examine the developmental trajectory and stability of neuropsychological functions
and structural and functional connectivity from childhood to adolescence and young
adulthood;
4. To correlate the data from structural (morphometric, cortical thickness, gyrification,
fiber tract integrity) and functional connectivity (rsfMRI), neuropsychology (Executive
function, visual-spatial memory, sustained attention, variability), neurophysiology
(Stop-signal ERP) and ADHD core symptoms stratifying by the presence of ADHD, presence
of DAT1 and NET (SLC6A2) variants, proband-unaffected sibling dyads, and different
developmental stages.